We also found that our GBM cell-targeted imsEV, delivering IFN-γ mRNA and PD-L1 antibody, could reprogramme the immune microenvironment of the tumour from an immunosuppressive to an immune-stimulating phenotype. The gene discussed is CD274; the disease is glioblastoma.